Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,071 | -2,681 | -120 | 2,083 | 4,711 |
| Depreciation Amortization | 14 | 6 | 25 | 19 | 13 |
| Accounts payable and accrued liabilities | -79 | 322 | 750 | 721 | 378 |
| Other Working Capital | 5,725 | -127 | 982 | 752 | -214 |
| Other Operating Activity | 95 | -358 | -8,923 | -8,858 | -8,454 |
| Operating Cash Flow | $-5,317 | $-2,838 | $-7,286 | $-5,284 | $-3,567 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -19 | -19 | N/A | N/A | N/A |
| Investing Cash Flow | $-19 | $-19 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,417 | 5,417 | 14,030 | 14,030 | 14,030 |
| Other Financing Activity | 0 | 0 | -5 | -5 | -5 |
| Financing Cash Flow | $5,417 | $5,417 | $14,025 | $14,025 | $14,025 |
| Beginning Cash Position | 11,992 | 11,992 | 5,253 | 5,253 | 5,253 |
| End Cash Position | 12,073 | 14,552 | 11,992 | 13,995 | 15,711 |
| Net Cash Flow | $81 | $2,560 | $6,739 | $8,742 | $10,458 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,317 | -2,838 | -7,286 | -5,284 | -3,567 |
| Capital Expenditure | -19 | -19 | N/A | N/A | N/A |
| Free Cash Flow | -5,336 | -2,857 | -7,286 | -5,284 | -3,567 |